Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-199 pembrolizumab in metastatic castration-resistant prostate cancer
2015-003644-40Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in metastatic castration-resistant prostate cancer (mCRPC) (5 cohorts), sponsored by Merck & Co. Primary endpoints: Objective response rate and Safety and tolerability. Started Apr 2016; status: completed.
02
Drugs
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2015-003644-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003644-40.